“So that study should read out midyear.”

In context

“confidence that we can continue to play an important role in lung cancer beyond just in the targeted therapies like [ lorlatinib ]. For SV, we are very encouraged by the data we've seen for the combination of pembrolizumab plus SV in the PD-L1 high population, where we've previously chosen a small number -- a small cohort of patients that they all responded in the PD-L1 high to that combination. So the Phase III study that's ongoing of pembrolizumab versus pembrolizumab for SV, that study is recruiting well in the first-line setting, and we're confident for the readout for that study. And ongoing also is the second-line study, which is against docetaxel, which was encouraged by the previous data we've seen obviously in a single-arm experience with a median overall survival of 6.3 months. So that study should read out midyear. That's docetaxel versus SV second line powered for -- obviously, for overall survival. And if it's positive, as I said earlier, it will be clinically meaningful. And then ongoing studies being planned also for the broader population in combination with chemo plus pembrolizumab, and we will share some of the data later this year for the early data for that combination. In terms of 4404, at ASCO, we will share the Phase II data of 4404 monotherapy in first-line PD-L1 expressing non-small cell lung cancer. As you know, we recently shared data at AACR, where we repeated the preclinical and early data generated by [ Bio China ]. So we're really confident that this is a differentiated molecule. And the binding against VEGF is -- we've shown at AACR is better, is higher affinity than what's seen”